Medicaid Programs Are Slow to Cover GLP-1s, but That Could Soon Change

Most states do not cover GLP-1s and other obesity medications for Medicaid beneficiaries, according to a recent analysis. However, one of the report’s authors tells AIS Health, a division of MMIT, that more states are pondering whether to place GLP-1s on their formularies and weighing the drugs’ health benefits with their high costs.

The Strategies to Overcome and Prevent (STOP) Obesity Alliance and the Obesity Action Coalition (OAC) released the report on June 3 based on data from fee-for-service and managed Medicaid programs in 2023. STOP, which is housed within the Milken Institute School of Public Health at George Washington University, conducts research, makes policy recommendations and develops online resources. OAC is an advocacy organization with more than 80,000 members.

© 2024 MMIT
Tim Casey

Tim Casey

Tim has been a reporter and editor for newspapers, websites and magazines for more than 20 years, including 10 years covering health care business topics. He has a deep knowledge of the managed care industry and pharmacy benefit management. He also has experience covering medical conferences and clinical and legislative health care issues. In 2014, the Society for Advancing Business Editing and Writing selected Tim as one of 15 journalists to participate in a national symposium on the Affordable Care Act. Tim has a B.A. in Psychology from the University of Notre Dame and an M.B.A. from Georgetown University.

Related Posts

business-meeting
May 23

Plans Take Wait-and-See Approach to Vendors Promising Help with Weight Loss Medication Costs

READ MORE
pharmacist
May 23

2023 Drug Trends Included GLP-1s, Humira Biosimilars, $0 Cost Share

READ MORE
executives-and-chart
May 9

PBMs’ 1Q Earnings Calls Are All About Biosimilar, GLP-1 Programs

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today